Navigation Links
Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals' Lorcaserin Achieved Statistically Significant Weight Loss
Date:5/26/2011

ISTANBUL, May 26, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today presented meta-analyses of the three trials in the lorcaserin Phase 3 clinical trial program at ECO 2011, the 18th European Congress on Obesity. The analyses show that lorcaserin caused statistically significant weight loss compared to placebo at one year among 7,500 obese and overweight, diabetic and non-diabetic adults. The lorcaserin-mediated weight loss was associated with favorable changes in biomarkers that may be predictive of cardiovascular and metabolic risk and in quality of life.

Christen M. Anderson, M.D., Ph.D., Arena's Vice President, Lorcaserin Development, stated, "We are pleased to have the opportunity to share and discuss the results from the lorcaserin Phase 3 program with the European medical community at ECO, and we look forward to submitting a Marketing Authorization Application for regulatory approval of lorcaserin in Europe next year."

At one year, using Modified Intent-to-Treat with Last Observation Carried Forward analysis (MITT-LOCF) of the integrated results, 46.3% of lorcaserin 10 mg twice daily (BID) patients and 40.6% of lorcaserin 10 mg once daily (QD) patients achieved at least 5% weight loss, compared to 22.1% of patients on placebo, and 22.0% of lorcaserin 10 mg BID patients and 17.3% of lorcaserin 10 mg QD patients achieved at least 10% weight loss, compared to 8.3% of patients on placebo. Of the patients completing year one of the trials, 62.3% of lorcaserin 10 mg BID patients and 52.8% of lorcaserin 10 mg QD patients achieved at least 5% weight loss, compared to 32.0% of patients on placebo, and 33.5% of lorcaserin 10 mg BID patients and 25.5% of lorcaserin 10 mg QD patients achieved at least 10% weight loss, compared to 13.8% of patients on placebo. Notably, this meta-analysis included approximately 600 patients enrolled with type 2 diabetes, a
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
2. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
3. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
4. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
5. KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain
6. Onyx Pharmaceuticals Announces Updated Pivotal Carfilzomib Phase 2B Data
7. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
8. Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA
9. EntreMed ENMD-2076 Phase 2 Data to Be Presented at ASCO Annual Meeting
10. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
11. Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 17, 2015 Research and Markets ( ... "Medical Oxygen Systems - Global Strategic Business Report" ... the worldwide markets for Medical Oxygen Systems in US$ ... Systems, Oxygen Cylinders & Regulators, and Oxygen Conserving Devices. ... Canada , Japan ...
(Date:4/17/2015)... 17, 2015   IBA Molecular, a global ... today that it has signed a definitive agreement to ... (IBAM NA), to Illinois Health and Science (IHS). Under IHS ... independent company headquartered in Dulles, Virginia ... of new product and footprint synergies. IBA Molecular is ...
(Date:4/17/2015)... 17, 2015 TWi Pharmaceuticals, Inc. ("TWi", Stock ... USA , has obtained state sales ... It has been in close contact with the major ... have its own label specialty generic products sold through ... pharma market. According to IMS Health, the ...
Breaking Medicine Technology:Medical Oxygen Systems - 2015 Global Strategic Business Report Featuring Leading Players, Caire, Invacare & Philips Respironics 2Health Care System to Acquire IBA Molecular North America 2Health Care System to Acquire IBA Molecular North America 3
(Date:4/17/2015)... 17, 2015 Alcohol and Violence , ... notes that drinking and driving has been the focus ... same time, the link between alcohol and crime received ... and violence and sexual assault, and their relationship to ... NCADD, 5.3 million adults in America were drinking alcohol ...
(Date:4/17/2015)... 2015 From the day Dr. Todd Phillips ... non-profit organization has empowered young people to create meaningful change ... bring fresh water and the Gospel to all of Liberia ... March 17 and 27, students, faculty and staff raised $21,000 ... fresh water and the Good News of Jesus. , ...
(Date:4/17/2015)... April 17, 2015 Representatives Jim Himes ... and Treatment Act HR 1849 in congress on April ... and treatment for patients with the genetic disease. ... past, would be the first to create a federally ... treatment of hereditary hemorrhagic telangiectasia. This would effectively prevent ...
(Date:4/17/2015)... 2015 At the end of February ... the “Salute to the Oscars” in the Stardust Penthouse ... overlooking the impressive Los Angeles skyline. These events honoring ... Durkin, LA’s leading producer of sustainable product placement in ... world’s premier providers of eco-friendly and socially conscious products ...
(Date:4/17/2015)... April 17, 2015 Baptist Health and ... signed a partnership agreement designed to transform oncology care ... institutions have agreed to create a joint cancer program ... and translational research. Baptist MD Anderson Cancer Center is ... a single destination for highly coordinated, multidisciplinary cancer care ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3Health News:The Last Well and Liberty U’s TEN Initiative raises $21,000 to Bring Fresh Water & The Gospel to 7,000 Liberians 2Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Choices Recovery Speaks with Dakota Hood of “The Hunger Games” about Addiction in Hollywood 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3
... Inc. (OTC Bulletin Board: CARN) today said the ... be webcast live from the Kennedy I Room ... Healthcare Conference at New York City,s Palace Hotel ... The presentation will cover DelSite,s three key ...
... CAMBRIDGE, Mass., Nov. 5 Abt Associates has ... Office of Planning, Research,and Evaluation within the U.S. ... and Families (ACF) to lead a major evaluation,of ... and former recipients of Temporary Assistance for Needy ...
... Care Awareness Week, WASHINGTON, Nov. 5 ... coverage for long-term care expenses,according to new survey ... The survey found that many Baby Boomers have ... have not thought about,long-term care insurance. (Logo: ...
... Relaxation in large, sound- and light-proof tanks with ... stress-related pain. This has been shown by Sven-ke ... with a dissertation from Karlstad University in Sweden. ... have indicated: sleep was improved, patients felt more ...
... may be more accurate than existing biological signposts ... into advanced forms of the disease. , ... edition of the International Journal of Cancer, the ... prevent patients from unnecessarily undergoing aggressive cancer treatments. ...
... /Xinhua-PRNewswire-FirstCall/ -- China Holdings, Inc.,(OTC Bulletin Board: ... its subsidiaries engage in multiple China-focused business ... real,estate, and pharmaceuticals, announced today the Company ... exclusive rights to develop and construct,the 2nd ...
Cached Medicine News:Health News:Carrington's DelSite Presentation at Rodman & Renshaw Conference to be Webcast Live on November 7th 2Health News:Abt Associates to Lead Major Evaluation of Programs Aimed at Promoting Self-Sufficiency for Disadvantaged Families 2Health News:New Survey Finds One in Four Baby Boomers Erroneously Believe They Have Coverage for Long-Term Care Expenses 2Health News:New Survey Finds One in Four Baby Boomers Erroneously Believe They Have Coverage for Long-Term Care Expenses 3Health News:Floating effective for stress and pain 2Health News:Biomarker may be an early predictor of advanced breast cancer 2Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 2Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 3Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 4Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 5Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 6Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 7Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 8
... fibre bronchoscopy: The HF-compatible V series from ... fibre bronchoscopes are measured., ,The HF-compatible ... the FB-19TV, FB-18V and FB-15V models along ... pediatric FB-8V, offer much better image quality ...
... BRO-YP2 is Fujinon's pediatric ... outside diameter allows for ... The standard 2.0mm channel ... accessory passage in all ...
Large, bright images from a bronchoscope designed for routine examination and treatment....
... in a series of bronchofiberscopes with electrosurgical ... to meet the demand for expanded bronchoscopic ... a new control section and ergonomic design ... provides a wider field of view, a ...
Medicine Products: